Unknown

Dataset Information

0

Site-Specific Drug-Releasing Polypeptide Nanocarriers Based on Dual-pH Response for Enhanced Therapeutic Efficacy against Drug-Resistant Tumors.


ABSTRACT: To enhance effective drug accumulation in drug-resistant tumors, a site-specific drug-releasing polypeptide system (PEG-Phis/Pasp-DOX/CA4) was exploited in response to tumor extracellular and intracellular pH. This system could firstly release the embedded tumor vascular inhibitor (CA4) to transiently 'normalize' vasculature and facilitate drug internalization to tumors efficiently, and then initiate the secondary pH-response to set the conjugated active anticancer drug (DOX) free in tumor cells. The encapsulated system (PEG-Phis/DOX/CA4), both CA4 and DOX embedding in the nanoparticles, was used as a control. Comparing with PEG-Phis/DOX/CA4, PEG-Phis/Pasp-DOX/CA4 exhibited enhanced cytotoxicity against DOX-sensitive and DOX-resistant cells (MCF-7 and MCF-7/ADR). Moreover, PEG-Phis/Pasp-DOX/CA4 resulted in enhanced therapeutic efficacy in drug-resistant tumors with reduced toxicity. These results suggested that this site-specific drug-releasing system could be exploited as a promising treatment for cancers with repeated administration.

SUBMITTER: Dong Y 

PROVIDER: S-EPMC4440445 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Site-Specific Drug-Releasing Polypeptide Nanocarriers Based on Dual-pH Response for Enhanced Therapeutic Efficacy against Drug-Resistant Tumors.

Dong Yaqiong Y   Yang Jun J   Liu Hongmei H   Wang Tianyou T   Tang Suoqin S   Zhang Jinchao J   Zhang Xin X  

Theranostics 20150428 8


To enhance effective drug accumulation in drug-resistant tumors, a site-specific drug-releasing polypeptide system (PEG-Phis/Pasp-DOX/CA4) was exploited in response to tumor extracellular and intracellular pH. This system could firstly release the embedded tumor vascular inhibitor (CA4) to transiently 'normalize' vasculature and facilitate drug internalization to tumors efficiently, and then initiate the secondary pH-response to set the conjugated active anticancer drug (DOX) free in tumor cells  ...[more]

Similar Datasets

| S-EPMC4096223 | biostudies-literature
| S-EPMC3620673 | biostudies-literature
| S-EPMC6682152 | biostudies-literature
| S-EPMC9505369 | biostudies-literature
| S-EPMC5479270 | biostudies-literature
| S-EPMC5968781 | biostudies-literature
| S-EPMC6433829 | biostudies-literature
| S-EPMC3657469 | biostudies-literature
| S-EPMC4425410 | biostudies-literature
| S-EPMC7470123 | biostudies-literature